M. Thayer

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Targeting survivin and p53 in pediatric acute lymphoblastic leukemia

B. Druker, J. Tyner, B. Chang, 2011, Leukemia.

A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

R. Bejar, S. Howell, W. Rice, 2020 .

Frequent aneuploidy among normal human hepatocytes.

S. Strom, M. Grompe, A. Duncan, 2012, Gastroenterology.

Abstract CT239: Early clinical findings from a phase 1a/b dose escalation trial to evaluate the safety and tolerability of CG-806 in patients with relapsed or refractory CLL/SLL or non-Hodgkin's lymphomas

R. Bejar, W. Rice, S. Howell, 2020 .

A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

R. Bejar, S. Howell, W. Rice, 2020, Blood.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.